Imugene Ltd (ASX: IMU) Share Price and News

Price

Movement

( )

(20 mins delayed)

52 Week Range

-

 
1 Year Return

 

Imugene Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $179.21 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 7.58 billion
Earnings per share -0.018
Dividend per share N/A
Year To Date Return -35.14%
Earnings Yield N/A
Franking -
Share Price

Day Change

( )

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

Imugene Ltd (ASX: IMU)
Latest News

Two happy scientists analysing test results.
Healthcare Shares

'Market will see the value' in Imugene share price

Imugene shares might be in a slump, but the CEO is not giving up now.

Read more »

three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.
Share Gainers

Why Bell Financial, Downer, Imugene, and Vulcan shares are pushing higher

These ASX shares are ending the week on a positive note.

Read more »

Young businessman standing on the top of the mountain punching fist in the air.
Share Market News

Here are the top 10 ASX 200 shares today

It was a top day for ASX investors on Wednesday.

Read more »

Three rockets heading to space
Share Gainers

3 ASX All Ordinaries shares surging more than 10% today

These three ASX All Ordinaries shares are trouncing the benchmark index today.

Read more »

A scientist examining test results.
Opinions

Down 35% in a year, is the Imugene share price a buying opportunity right now?

Is a 35% discount enticing enough to invest in this clinical-stage biotech. Here's my take.

Read more »

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Share Gainers

Here are the top 10 ASX 200 shares today

Did you own the mining stock that outperformed the rest of the ASX 200 on Friday?

Read more »

three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.
Share Gainers

Why Boral, Imugene, Nickel Industries, and Sigma shares are rising today

These ASX shares are having a strong finish to the week.

Read more »

Three young people in business attire sit around a desk and discuss.
Share Market News

3 All Ords stocks making major moves on big news today

Let's dive into today's news from the All Ordinaries trio.

Read more »

Two fists connect in a surge of power, indicating strong share price growth or new partnerships for ASC mining and resource companies
Share Gainers

Here are the top 10 ASX 200 shares today

It was a great day to be invested in this ASX 200 energy stock.

Read more »

A woman looks distressed as she stares dramatically at her phone
Share Fallers

Why Allkem, Argosy Minerals, Audio Pixels, and Imugene shares are falling

These ASX shares are having a tough time on Thursday.

Read more »

A woman wearing yellow smiles and drinks coffee while on laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

Guess which ASX 200 stock defied today's downturn to gain 4.8%.

Read more »

Five people in an office high five each other.
Share Gainers

Here are the top 10 ASX 200 shares today

One ASX 200 tech share outperformed all others on Friday.

Read more »

Frequently Asked Questions

IMU ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Imugene Ltd

Imugene Ltd (ASX: IMU) is a biotechnology company working in cancer immunotherapy.

The company specialises in clinical-stage immuno-oncology therapies. Its product pipeline includes Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard-care drugs and immunotherapies.

The company's lead product is HER-Vaxx, a proprietary cancer vaccine for the treatment of gastric and breast cancer, where the cancer is HER-2 positive. The vaccine has demonstrated it stimulates a polyclonal antibody response to HER2/neu. 

Imugene's various immunotherapy products are involved in ongoing clinical trials involving cancer specialists and researchers worldwide.

IMU Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
02 May 2025 $0.02 $0.00 0.00% 11,265,533 $0.02 $0.02 $0.02
01 May 2025 $0.02 $0.00 0.00% 8,572,400 $0.02 $0.03 $0.02
30 Apr 2025 $0.02 $0.00 0.00% 28,700,582 $0.02 $0.03 $0.02
29 Apr 2025 $0.03 $0.00 0.00% 17,181,883 $0.03 $0.03 $0.02
28 Apr 2025 $0.03 $0.00 0.00% 4,329,344 $0.03 $0.03 $0.03
24 Apr 2025 $0.03 $0.00 0.00% 11,658,037 $0.03 $0.03 $0.03
23 Apr 2025 $0.03 $0.00 0.00% 28,590,644 $0.02 $0.03 $0.02
22 Apr 2025 $0.02 $0.00 0.00% 8,328,723 $0.02 $0.02 $0.02
17 Apr 2025 $0.02 $0.00 0.00% 34,372,350 $0.02 $0.03 $0.02
16 Apr 2025 $0.03 $0.00 0.00% 14,449,766 $0.03 $0.03 $0.03
15 Apr 2025 $0.03 $0.00 0.00% 18,432,396 $0.03 $0.03 $0.03
14 Apr 2025 $0.03 $0.00 0.00% 7,725,833 $0.03 $0.03 $0.03
11 Apr 2025 $0.02 $0.00 0.00% 10,760,349 $0.02 $0.03 $0.02
10 Apr 2025 $0.02 $0.00 0.00% 16,098,086 $0.03 $0.03 $0.02
09 Apr 2025 $0.02 $0.00 0.00% 31,660,115 $0.03 $0.03 $0.02
08 Apr 2025 $0.03 $0.00 0.00% 18,642,455 $0.03 $0.03 $0.03
07 Apr 2025 $0.02 $0.00 0.00% 35,373,653 $0.02 $0.03 $0.02
04 Apr 2025 $0.03 $0.00 0.00% 38,080,420 $0.03 $0.03 $0.03

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
14 Feb 2025 Leslie (Mi Ok) Chong Exercise 4,828,125 $207,609
Conversion of securities. 1,25,53,125 Performance Rights Award
14 Feb 2025 Leslie (Mi Ok) Chong Issued 4,828,125 $207,609
Conversion of securities.
14 Feb 2025 Leslie (Mi Ok) Chong Issued 19,312,500 $830,437
Employee Share Ownership Plan. 31,865,625 - Performance Rights Award
14 Feb 2025 Paul Hopper Exercise 894,094 $38,446
Conversion of securities. 20,32,031 Performance Rights Award
14 Feb 2025 Paul Hopper Issued 3,576,375 $153,784
Employee Share Ownership Plan. 5,608,406 - Performance Rights Award
14 Feb 2025 Paul Hopper Issued 894,094 $38,446
Conversion of securities.
14 Feb 2025 Lesley Russell Issued 2,000,000 $86,000
Employee Share Ownership Plan. 2,750,000 - Restricted Stock Units (RSUs)
14 Feb 2025 Jakob Dupont Issued 2,000,000 $86,000
Employee Share Ownership Plan. 2,750,000 - Restricted Stock Units
14 Feb 2025 Kim Drapkin Issued 2,000,000 $86,000
Employee Share Ownership Plan. 2,750,000 Restricted Stock Units
01 Jul 2024 Kim Drapkin Exercise 250,000 $13,750
Conversion of securities. 750,000 - Restricted Stock Units
01 Jul 2024 Kim Drapkin Issued 250,000 $13,750
Conversion of securities. As per announcement on 08-07-2024
01 Jul 2024 Jens Eckstein Exercise 250,000 $13,750
Conversion of securities. 750,000 RSU
01 Jul 2024 Jens Eckstein Issued 250,000 $13,750
Conversion of securities.
01 Jul 2024 Jakob Dupont Issued 250,000 $13,750
Conversion of securities.
01 Jul 2024 Jakob Dupont Exercise 250,000 $13,750
Conversion of securities. 750,000 - Restricted Stock Units
01 Jul 2024 Lesley Russell Issued 250,000 $13,750
Conversion of securities.
01 Jul 2024 Lesley Russell Exercise 250,000 $13,750
Conversion of securities. 750,000 - Restricted Stock Units
01 Jul 2024 Paul Hopper Issued 975,375 $53,645
Conversion of securities.
01 Jul 2024 Paul Hopper Exercise 975,375 $53,645
Conversion of securities. 2,926,125 PERFORMANCE RIGHTS AWARD
01 Jul 2024 Leslie (Mi Ok) Chong Exercise 5,793,750 $318,656
Conversion of securities. 17,381,250 RIGHTS
01 Jul 2024 Leslie (Mi Ok) Chong Transfer 1,500,000 $82,500
As advised by the company. Transfer from direct to indirect holding
01 Jul 2024 Leslie (Mi Ok) Chong Buy 5,793,750 $318,656
Conversion of securities.
01 Jul 2024 Leslie (Mi Ok) Chong Transfer 1,500,000 $82,500
As advised by the company. Transfer from direct to indirect holding

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Leslie (Mi Ok) Chong Chief Executive OfficerManaging Director Nov 2016
Ms Chong joined the Group from the leading oncology clinical development company, Genentech (a member of the Roche family), where she was a Senior Clinical Program Lead at the head office in San Francisco. She has over 25 years of experience in leading clinical and department development in oncology. In November 2016, Former directorships in last three years - Cure Brain Cancer Foundation (non-profit organisation), until 11 April 2023.
Mr Paul Alex Hopper Executive ChairmanExecutive Director Dec 2013
Mr Hopper has over 20 years of experience in the management and funding of biotechnology and healthcare public companies as chairman, chief executive officer and director in Australia and the United States. Mr Hopper's sector experience has covered therapeutic areas with emphasis on immunotherapy. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States. Former directorships in last three years include Scopus BioPharma Inc (NASDAQ: SCPS), until 18 May 2022.
Dr Lesley Russell Non-Executive Director Apr 2019
Dr Russell is a haematologist/oncologist and has over 25 years of experience and leadership in the international pharmaceutical field as a Chief Medical Officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology and has had new drug approvals with FDA and European Medicines Agency. Dr Russell has experience as a director of NASDAQ listed pharmaceutical companies. She is a member of the Royal College of Physicians UK. Other current directorships - Enanta Pharmaceuticals (NASDAQ: ENTA), since 22 November 2016. Dr Russell is member of Risk Committee.
Dr Jakob Dupont Non-Executive Director Sep 2022
Dr Dupont is an industry and drug development expert with more than 20 years of experience specialising in oncology and other therapeutic areas. Dr Dupont is currently the Executive Venture Partner at Sofinnova Investments. Dr Dupont's experience includes NASDAQ listed Atara Biotherapeutics (NASDAQ: ATRA), where he oversaw all research and development, including three clinical stage programs spanning Phase 1 through to Phase 3, and preclinical programs. Other current directorships include Pyxis Oncology (NASDAQ: PYXS); Avenzo Therapeutics and Flagship Pioneering (Scientific Advisory Board). Former directorships in last three years - Apexigen (NASDAQ: APGN) until August 2023. Dr Dupont is member of the Risk Committee.
Ms Kim Drapkin Non-Executive Director Jun 2023
Ms Drapkin has over 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. In addition to Imugene, Ms Drapkin currently serves on the board of directors at Acumen Pharmaceuticals (NASDAQ: ABOS) where she chairs the audit committee and is a member of the compensation committee and LENZ Therapeutics (NASDAQ: LENZ) where she is a member of the compensation and governance committees. Recently, Ms Drapkin was CEO and a board member at Graphite Bio where she led the strategic alternatives process culminating in a reverse merger with LENZ Therapeutics. Prior to that, Ms Drapkin was CFO at Jounce Therapeutics since its inception, playing a role in building Jounce's financial infrastructure. Prior to joining Jounce, Ms Drapkin owned a financial consulting firm where she served as the interim chief financial officer for early stage biotechnology companies. Previously, Ms Drapkin was chief financial officer at EPIX Pharmaceuticals. Prior to EPIX, Ms Drapkin spent ten years in roles of increasing responsibility within the finance organisation at Millennium Pharmaceuticals. Ms Drapkin began her career in the technology and life sciences practice at PriceWaterhouseCoopers LLP. Other current directorships are held with Acumen Pharmaceuticals (NASDAQ: ABOS); LENZ Therapuetics (NASDAQ: LENZ). Former directorships in last three years - Yumanity Therapeutics (NASDAQ: YMTX); Proteostasis Therapeutics (NASDAQ: PTI). She is chair of risk committee.
Mr Darren Keamy Chief Financial OfficerCompany Secretary Mar 2025
-
Monil Shah Chief Business Officer
-
Mike Tonroe Chief Financial Officer
-
Darren Keamy Chief Financial OfficerCompany Secretary
-
Paul Woodard Chief Medical Officer
-
Bradley Glover Chief Operating Officer
-
Nicholas Ede Chief Technology Officer
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Paul Hopper 409,071,906 5.57%
JP Morgan 283,996,697 3.86%
Citicorp Nominees Pty Limited 266,813,810 3.63%
Mann Family 265,582,609 3.61%
HSBC Custody Nominees (Australia) Limited i 213,532,203 2.91%
Dr Nicolas Smith 118,000,000 1.61%
Netwealth Investments Limited <Wrap Ser Vices A/C> 85,488,611 1.16%
Mi Ok Chong 78,416,666 1.07%
BNP Paribas Noms Pty Ltd 70,407,583 0.96%
National Nominees Pty Ltd 60,113,645 0.82%
UBS Nominees Pty Ltd 50,328,041 0.68%
BNP Paribas Noms Pty Ltd <Ib Au Noms Retail Client> 48,979,324 0.67%
HSBC Custody Nominees (Australia) Limited ii 29,079,510 0.40%
Mr Phillip Wood 25,480,000 0.35%
Sve Capital Pty Ltd <Strategic Vision Unit A/C> 23,000,000 0.31%
Dr Yuman Fong 22,379,032 0.30%
Dr Jen Eckstein 20,738,095 0.28%
Dr Lesley Russell 20,238,095 0.28%
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 20,230,709 0.28%
Mr Scott Spencer Pappin & Mrs Tracey Lee Pappin <Pappin Super Fund A/C> 20,000,000 0.27%
Jem Investment Fund Holdings Pty Ltd <Jem Invest Fund Family A/C> 20,000,000 0.27%

Profile

since

Note